Don't Become Another Statistic in this American Epidemic

Don’t Become Another Statistic in this American Epidemic

by | published August 18th, 2018

Imagine if only 1 out of every 5 nuclear tests were reliable.

Or if 4 out of every 5 oil rigs failed to retrieve oil.

Or if 8 out of 10 solar panels refused to soak up the sun.

In the energy business, you can bet your bottom dollar that those errors would be immediately detected and resolved.

And yet we can’t seem to get our act together in the medical industry, arguably the most important we have.

I’m nearly 70 years old.

I know that I’m at risk for many different health problems, so I go to my doctor religiously to get tested and make sure I’m still healthy.

But I recently learned that that might not be enough.

See, every 18 minutes, a medical killer takes the life of an American male.

Some people might argue that there are many types of diseases with the same or worse statistics.

But many of those diseases are undetectable.

This one is not.

But the test doesn’t detect it.

Let me repeat that.

This test, designed to detect this disease, doesn’t actually do its job.

In fact, it has an up to 8 out of 10 inaccuracy rate.

That’s astronomical for a test designed to detect a known disease that is the second-leading cause of cancer death in men in the U.S.

And every year, 30 million American men take this test…

Public Service Announcement: The PSA Problem

This disease is not what you might think.

The leading cancer risk for American men over the age of 50 is not lung cancer, skin cancer, or even brain cancer.

It’s prostate cancer, and it’s reached near-epidemic levels.

In fact, an American male is diagnosed with prostate cancer every three minutes.

But that’s not taking into account the amount of men who aren’t being diagnosed.

My friend and colleague Ernie Tremblay is the Director of Scientific Research at Money Map Press.

He told me about the shocking behind-the-scenes problems with the testing for prostate cancer.

Unlike many cancers, there are usually no symptoms of prostate cancer. No pain, no real warning signs, nothing to let you know that the clock has begun ticking.

In the early stages, the cancer cells are nearly identical to healthy cells – making them impossible to detect.

The test measures the presence of prostate-specific antigens circulating in your bloodstream. The thinking goes, if your PSA levels are high, you are at high risk for cancer.

That would be fantastic if only the test worked consistently.

Dr. Steven Salzberg, Professor at Johns Hopkins University, has stated that the PSA test can deliver “inaccurate results up to 80% of the time.”

These inaccuracies gives men with false negatives – and false positives, which lead to unnecessary invasive procedures that can often leave men with permanent disabilities.

That’s eight out of ten men receiving an incorrect reading from a test that’s hailed as an early detection method.

But times are about to change…

Save Lives – And Mint Millionaires

Ernie has found a tiny, $7 company that has developed a breakthrough solution that could protect 50 million American men from the ravages of prostate cancer.

This company has developed “radio-equipped molecules.” These molecules are so small that you could fit a million of them on the head of a pin.

But small doesn’t mean weak.

In fact, these molecules are like microscopic bounty hunters, designed to scour your body in search of prostate cancer cells, and can give doctors a new, accurate way to locate them.

With a 94% accuracy rate, this could change how we locate and diagnose prostate cancer.

And lower the rate of Americans dying unnecessarily because they were undiagnosed.

This new technology gives this company an edge in the medical industry.

An edge of a potential 72,500% sales surge with their phase-3 trial results set to arrive no later than September 30.

Which means that if you want the chance to profit from this company, and contribute to the potential solution of the cancer problem, you’ll need to do it soon.

Just click here to find out more.



Please Note: Kent cannot respond to your comments and questions directly. But he can address them in future alerts... so keep an eye on your inbox. If you have a question about your subscription, please email us directly at

  1. No comments yet.
  1. No trackbacks yet.